# ETCTN 10388 (NCT04234568)

> Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

No report yet. It can be ordered.

- Drugs tested: triapine plus lutetium-177 dotatate
- Indication: well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04234568
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Neuroendocrine Tumor
- Interventions: Biospecimen Collection; Computed Tomography; Lutetium Lu 177 Dotatate; Magnetic Resonance Imaging; Triapine
- Enrollment: 31
- Primary outcome: Maximum Tolerated Dose (MTD) of Triapine and Recommended Phase 2 Dose (RP2D)
- Primary outcome: Dose Limiting Toxicity (DLT)

## Indexed commentary on ETCTN 10388 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 12 posts on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=etctn-10388-nct04234568

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04234568", "email": "<work email>"}; the inbox owner confirms by the emailed link.